Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus.,Journal of Cellular Physiology

当前位置： X-MOL 学术 › J. Cell. Physiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus.
Journal of Cellular Physiology ( IF 4.5 ) Pub Date : 2020-06-24 , DOI: 10.1002/jcp.29879
Chang Guo ₁ , Li Zhao ₁ , Yanyan Li ₁ , Xia Deng ₁ , Guoyue Yuan ₁

Affiliation

Sedentary and high‐calorie diets are associated with increased risk of obesity and type 2 diabetes mellitus, while exercise and diet control are also important nondrug treatments for diabetes. Fibroblast growth factor 21 (FGF21) is an important cytokine, which is mainly expressed in liver, fat and muscle tissue responding to nutrition and exercise, and plays an important role in the improvement of glucose and lipid metabolism. Due to the increasing serum FGF21 level in obesity and diabetes, FGF21 can be used as a predictor or biomarker of diabetes. A variety of clinical antidiabetic drugs can reduce the content of FGF21, possibly for the improvement of FGF21 sensitivity. In this paper, we reviewed the interactions between FGF21 and nondrug therapy (diet and exercise) for diabetes and explored the potential value of the combined application of clinical antidiabetic drugs and FGF21.

中文翻译：

FGF21与2型糖尿病药物或非药物治疗的关系。

久坐和高热量饮食与肥胖和 2 型糖尿病风险增加有关，而运动和饮食控制也是糖尿病的重要非药物治疗方法。成纤维细胞生长因子21（FGF21）是一种重要的细胞因子，主要表达于对营养和运动有反应的肝脏、脂肪和肌肉组织中，在改善糖脂代谢中起重要作用。由于肥胖和糖尿病患者血清 FGF21 水平升高，因此 FGF21 可用作糖尿病的预测因子或生物标志物。临床上多种降糖药均可降低FGF21的含量，可能是为了提高FGF21的敏感性。在本文中，

更新日期：2020-06-25

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南